InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Thursday. The firm issued a sell rating on the stock.

InspireMD Trading Down 0.5 %

NSPR stock opened at $2.00 on Thursday. The company’s 50 day moving average is $2.30 and its 200 day moving average is $2.62. The stock has a market cap of $46.80 million, a price-to-earnings ratio of -1.85 and a beta of 0.92. InspireMD has a 1-year low of $1.29 and a 1-year high of $3.85.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 320.97% and a negative return on equity of 55.71%. The business had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.65 million. During the same period in the previous year, the firm posted ($0.60) earnings per share. As a group, sell-side analysts forecast that InspireMD will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. bought a new position in InspireMD, Inc. (NYSE:NSPR) during the first quarter, according to its most recent 13F filing with the SEC. The fund bought 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned about 0.13% of InspireMD as of its most recent SEC filing. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.